

19 June 2019  
EMA/289298/2019  
Veterinary Medicines Division

## Monthly report on application procedures, guidelines and related documents for veterinary medicines

March 2019

This report, which is updated every month, provides current information related to the volume and evaluation of pre- and post-authorisation applications for medicinal products for veterinary use received by the European Medicines Agency (EMA) for the current and previous three years on:

- scientific advice requests;
- applications for initial evaluations, extensions, variations and renewals concerning marketing authorisations (MAs);
- applications for initial evaluations, extensions, modifications and extrapolations for maximum residue limits (MRLs);
- arbitration and referral procedures;
- requests for classification and re-classifications of products as Minor Use Minor Species (MUMS)/limited market.

In addition, the report includes a summary table of the opinions issued by the Committee for Medicinal Products for Veterinary Use (CVMP) in the current year, as well as a list of adopted guidelines and other public guidance documents.


The purpose is only to provide ongoing factual information. Commentaries and analysis are provided in the Agency's annual reports.



## Statistics on pre- and post-authorisation applications for medicinal products for veterinary use


Scientific advice requests				
	2016	2017	2018	2019
Submitted and validated	18	17	25	6
Advice given	18	20	23	3

Scientific advice requests submitted and advice given



Initial evaluation of marketing authorisation applications				
	2016	2017	2018	2019
Full (submitted)	18	12	11	1
Abridged/generics (submitted)	3	5	4	4
Withdrawals	1	1	3	0
Positive opinions <sup>1</sup>	11	17(1)	10	6(2)
Negative opinions <sup>1</sup>	1	0	3	(1)

MMA submissions and outcomes



<sup>1</sup> Full (submitted) □ Abridged/generics (Submitted) □ Withdrawals □ Positive opinions □ Negative opinions

<sup>1</sup> Re-examination or re-consideration (request by European Commission) of opinion are in brackets

### Marketing authorisations

	2016	2017	2018	2019
Granted	7	18	9	<b>5</b>
Withdrawals	1	0	5	<b>0</b>
Refusal	0	0	1	<b>0</b>
Not renewed	1	0	2	<b>0</b>


### Extensions — applications

	2016	2017	2018	2019
Submitted	3	5	1	<b>0</b>
Withdrawals	0	0	0	<b>0</b>
Positive opinions	5	2	5	<b>1</b>
Negative opinions	0	0	0	<b>0</b>

### Variations — applications submitted

	2016	2017	2018	2019
Type-IA variations	243	238	330	<b>98</b>
Type-IB variations	126	130	147	<b>40</b>
Type-II variations	41	78	112	<b>17</b>
Transfers	5	3	17	<b>2</b>

**Post-authorisation: submissions of variations and transfers**



### Renewals — applications

	2016	2017	2018	2019
Submitted	13	9	24	<b>1</b>
Positive opinions	14	10	15	<b>12</b>
Negative opinions	0	0	0	<b>0</b>

### Establishment of MRLs for new substances<sup>2</sup> — applications

	2016	2017	2018	2019
Submitted	6	3	3	0
Withdrawals	0	2	2	0
Positive opinions <sup>3,4</sup>	2	4	1	1
Negative opinions	0	0	0	0

### Extensions/modifications of MRLs<sup>5</sup> — applications

	2016	2017	2018	2019
Submitted	1	3	1	0
Withdrawals	1	0	0	0
Positive opinions <sup>3</sup>	3	2	2	0
Negative opinions	0	0	0	0


### Review of opinions/extrapolations of MRLs<sup>6</sup>

	2016	2017	2018	2019
Submitted	0	0	1	1
Opinion <sup>3</sup>	0	0	1	0

### Substances considered as not falling within the scope of Regulation (EC) No 470/2009 — requests

	2016	2017	2018	2019
Submitted	4	4	2	0
Agreed	3	2	1	0
Not agreed	0	0	0	0
Scientific advice recommended	1	1	2	0

### MRL-related submissions



<sup>2</sup> Establishment of MRLs for new substances under article 3 of Regulation (EC) No 470/2009.


<sup>3</sup> Including opinions recommending the extension of the expiry date for provisional MRLs or definitive MRLs for substances previously with provisional MRLs.

<sup>4</sup> Re-examinations of opinions are indicated in brackets.

<sup>5</sup> Extension or modification of MRLs under article 3 of Regulation (EC) No 470/2009.


<sup>6</sup> Review of opinions under article 11 of Regulation (EC) No 470/2009 or requests under article 27 of Regulation (EC) No 470/2009.

MUMS/limited market (re)classification requests — outcome				
	2016	2017	2018	2019
MUMS/limited market with financial incentives	1	3	1	1
MUMS/limited market without financial incentives	17	15	15	10
MUMS/limited market reclassification with financial incentives	1	2	0	1
MUMS/limited market reclassification without financial incentives	3	7	5	1
Not MUMS/limited market	3	2	7	1



Arbitrations and referrals				
	2016	2017	2018	2019
Arbitrations and referrals submitted	8	1	5	2
Opinions <sup>7</sup>	7	7(1)	3(1)	1

**Arbitrations and referrals submissions and opinions**



<sup>7</sup> Re-examinations of opinions are in brackets.

## CVMP opinions in 2019 on medicinal products for veterinary use

### Positive opinions

Product	Marketing authorisation holder	Target species	Regulatory information
<ul style="list-style-type: none"> <li>Invented name</li> <li>INN/Common name</li> </ul>			<ul style="list-style-type: none"> <li>Procedure number</li> <li>Opinion date</li> </ul>
<ul style="list-style-type: none"> <li>Chanhold</li> <li>selamectin</li> </ul>	<ul style="list-style-type: none"> <li>Chanelle Pharmaceuticals Manufacturing Ltd.</li> </ul>	<ul style="list-style-type: none"> <li>Cats and Dogs</li> </ul>	<ul style="list-style-type: none"> <li>EMEA/V/C/004265/0000</li> <li>21/02/2019</li> </ul>
<ul style="list-style-type: none"> <li>Felisecto Plus</li> <li>selamectin/sarolaner</li> </ul>	<ul style="list-style-type: none"> <li>Zoetis Belgium SA</li> </ul>	<ul style="list-style-type: none"> <li>Cats</li> </ul>	<ul style="list-style-type: none"> <li>EMEA/V/C/005093/0000</li> <li>21/02/2019</li> </ul>
<ul style="list-style-type: none"> <li>Forceris</li> <li>toltrazuril/iron (as gleptoferron)</li> </ul>	<ul style="list-style-type: none"> <li>Ceva Santé Animale</li> </ul>	<ul style="list-style-type: none"> <li>Piglets</li> </ul>	<ul style="list-style-type: none"> <li>EMEA/V/C/004329/0000</li> <li>21/02/2019</li> </ul>
<ul style="list-style-type: none"> <li>ReproCyc ParvoFLEX</li> <li>porcine parvovirosis vaccine (inactivated)</li> </ul>	<ul style="list-style-type: none"> <li>Boehringer Ingelheim Vetmedica GmbH</li> </ul>	<ul style="list-style-type: none"> <li>Pigs</li> </ul>	<ul style="list-style-type: none"> <li>EMEA/V/C/004858/0000</li> <li>21/02/2019</li> </ul>
<ul style="list-style-type: none"> <li>HorStem</li> <li>Equine umbilical cord mesenchymal stem cells</li> </ul>	<ul style="list-style-type: none"> <li>EquiCord-Ymas S.L.</li> </ul>	<ul style="list-style-type: none"> <li>Horses</li> </ul>	<ul style="list-style-type: none"> <li>EMEA/V/C/004265/0000</li> <li>21/02/2019</li> <li>(re-examination)</li> </ul>
<ul style="list-style-type: none"> <li>Afoxolaner Merial</li> <li>Afoxolaner</li> </ul>	<ul style="list-style-type: none"> <li>Merial</li> </ul>	<ul style="list-style-type: none"> <li>Dogs</li> </ul>	<ul style="list-style-type: none"> <li>EMEA/V/C/005126/0000</li> <li>21/03/2019</li> </ul>
<ul style="list-style-type: none"> <li>Baycox Iron</li> <li>TOLTRAZURIL/IRON(III) ION</li> </ul>	<ul style="list-style-type: none"> <li>Bayer Animal Health GmbH</li> </ul>	<ul style="list-style-type: none"> <li>Piglets</li> </ul>	<ul style="list-style-type: none"> <li>EMEA/V/C/004794/0000</li> <li>21/03/2019</li> </ul>

### Negative opinions

Product	Applicant	Target species	Regulatory information
<ul style="list-style-type: none"> <li>Invented name</li> <li>INN/Common name</li> </ul>			<ul style="list-style-type: none"> <li>Procedure number</li> <li>Opinion date</li> </ul>
<ul style="list-style-type: none"> <li>None</li> </ul>	<ul style="list-style-type: none"> <li>None</li> </ul>	<ul style="list-style-type: none"> <li>None</li> </ul>	<ul style="list-style-type: none"> <li>None</li> </ul>

## CVMP opinions in 2019 on establishment of MRLs

### ***Positive opinions***

<b>Product</b>	<b>Target species</b>	<b>Regulatory information</b>
• Substance		• Procedure number • Opinion date
• Ciclesonide	• Horses	• EMEA/V/MRL/005010/FULL/0001 • 21/02/2019

## Arbitrations and referrals in 2019

### *Ongoing procedures*

Type of procedure	Date	Product
	<ul style="list-style-type: none"> <li>• Clock start</li> <li>• CVMP opinion</li> </ul>	<ul style="list-style-type: none"> <li>• Product name</li> <li>• INN</li> </ul>
<ul style="list-style-type: none"> <li>• Referral under Article 35 of Directive 2001/82/EC</li> </ul>	<ul style="list-style-type: none"> <li>• 14/02/2018</li> <li>• 21/02/2019</li> </ul>	<ul style="list-style-type: none"> <li>• Veterinary medicinal products containing 50 mg closantel per ml presented as solutions for injection for subcutaneous use in sheep</li> <li>• Closantel</li> </ul>
<ul style="list-style-type: none"> <li>• Referral under Article 35 of Directive 2001/82/EC</li> </ul>	<ul style="list-style-type: none"> <li>• 10/10/2018</li> </ul>	<ul style="list-style-type: none"> <li>• Veterinary medicinal products containing paromomycin to be administered parenterally to pigs</li> <li>• Paromomycin</li> </ul>
<ul style="list-style-type: none"> <li>• Referral under Article 35 of Directive 2001/82/EC</li> </ul>	<ul style="list-style-type: none"> <li>• 10/10/2018</li> </ul>	<ul style="list-style-type: none"> <li>• Veterinary medicinal products containing tylosin presented as solution for injection to be administered to sheep</li> <li>• Tylosin</li> </ul>
<ul style="list-style-type: none"> <li>• Referral under Article 35 of Directive 2001/82/EC</li> </ul>	<ul style="list-style-type: none"> <li>• 23/01/2019</li> </ul>	<ul style="list-style-type: none"> <li>• Veterinary medicinal products containing tylosin base (as a single active substance) presented as solutions for injection for intramuscular use in pigs</li> <li>• Tylosin base</li> </ul>
<ul style="list-style-type: none"> <li>• Referral under Article 35 of Directive 2001/82/EC</li> </ul>	<ul style="list-style-type: none"> <li>• 21/02/2019</li> </ul>	<ul style="list-style-type: none"> <li>• Betamox LA 150mg/ml Suspension for Injection and its associated names, and generic products thereof</li> <li>• Amoxicillin</li> </ul>

## Guidelines and working documents in 2019

### *CVMP Quality*

Reference number	Document title	Status
	Questions and answers on the use of peptone in the manufacture of active substances via fermentation process	Adopted March 2019

### *General*

Reference number	Document title	Status
<a href="#">EMA/CVMP/VICH/517152/2013</a>	VICH GL57: Studies to evaluate the metabolism and residue kinetics of veterinary drugs in food-producing species: marker residue depletion studies to establish product withdrawal periods in aquatic species	Adopted March 2019
<a href="#">EMA/CVMP/VICH/467/2003</a>	VICH GL36(R2) Studies to evaluate the safety of residues of veterinary drugs in human food: general approach to establish a microbiological ADI	Adopted March 2019